



#11

## SUBSTITUTE SEQUENCE LISTING

<110> UNIVERSITY OF ALBERTA  
WARREN, KENNETH G.

<120> PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND  
THE ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO  
MULTIPLE SCLEROSIS PATIENTS

<130> 098810/027 8741

<140> 09/813,383

<141> 2001-03-20

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 170

<212> PRT

<213> Homo sapiens

<220>

<221> misc-feature

<223> Human myelin basic protein

<400> 1

Ala	Ser	Gln	Lys	Arg	Pro	Ser	Gln	Arg	His	Gly	Ser	Lys	Tyr	Leu	Ala
1			5						10					15	
Thr	Ala	Ser	Thr	Met	Asp	His	Ala	Arg	His	Gly	Phe	Leu	Pro	Arg	His
			20					25					30		
Arg	Asp	Thr	Gly	Ile	Leu	Asp	Ser	Ile	Gly	Arg	Phe	Phe	Gly	Gly	Asp
		35					40					45			
Arg	Gly	Ala	Pro	Lys	Arg	Gly	Ser	Gly	Lys	Asp	Ser	His	His	Pro	Ala
	50					55					60				
Arg	Thr	Ala	His	Tyr	Gly	Ser	Leu	Pro	Gln	Lys	Ser	His	Gly	Arg	Thr
65					70					75				80	
Gln	Asp	Glu	Asn	Pro	Val	Val	His	Phe	Phe	Lys	Asn	Ile	Val	Thr	Pro
			85						90					95	
Arg	Thr	Pro	Pro	Pro	Ser	Gln	Gly	Lys	Gly	Arg	Gly	Leu	Ser	Leu	Ser
		100					105						110		
Arg	Phe	Ser	Trp	Gly	Ala	Glu	Gly	Gln	Arg	Pro	Gly	Phe	Gly	Tyr	Gly
	115						120					125			
Gly	Arg	Ala	Ser	Asp	Tyr	Lys	Ser	Ala	His	Lys	Gly	Phe	Lys	Gly	Val
	130					135					140				
Asp	Ala	Gln	Gly	Thr	Leu	Ser	Lys	Ile	Phe	Lys	Leu	Gly	Gly	Arg	Asp
145					150					155				160	
Ser	Arg	Ser	Gly	Ser	Pro	Met	Ala	Arg	Arg						
			165						170						

<210> 2  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2  
Val His Phe Phe Lys Asn Ile  
1 5

<210> 3  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 3  
Lys Ser His Gly Arg Thr Gln Asp Glu Asn Pro Val Val His Phe Phe  
1 5 10 15

Lys Asn Ile Val Thr  
20

<210> 4  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 4  
Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys Ser His Gly  
1 5 10 15

<210> 5  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 5  
His His Pro Ala Arg Thr Ala His Tyr Gly Ser Leu Pro Gln Lys  
1 5 10 15

<210> 6  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 6  
Tyr Gly Ser Leu Pro Gln Lys Ser His Gly Arg Thr Gln Asp Glu  
1 5 10 15

<210> 7  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 7  
Thr Gln Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr  
1 5 10 15

Pro Arg

<210> 8  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 8  
Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys Gly  
1 5 10 15

<210> 9  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 9  
Asn Pro Val Val His Phe Phe Lys Asn Ile  
1 5 10

<210> 10  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 10  
Pro Val Val His Phe Phe Lys Asn Ile Val  
1 5 10

<210> 11  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 11  
Val Val His Phe Phe Lys Asn Ile Val Thr Pro  
1 5 10

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 12

Val His Phe Phe Lys Asn Ile Val Thr Pro  
1 5 10